Drug-induced phospholipidosis: are there functional consequences?
1Department of Physiology, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA. mreasor@hsc.wvu.edu
Experimental Biology and Medicine (Maywood, N.J.)
|September 25, 2001
Summary
Cationic amphiphilic drugs (CADs) can cause phospholipidosis, a condition marked by cellular phospholipid buildup. This review evaluates the functional consequences of this drug-induced condition.
Area of Science:
- Pharmacology
- Cell Biology
- Toxicology
Background:
- Phospholipidosis is a condition characterized by intracellular phospholipid accumulation and lamellar body formation.
- It is induced by cationic amphiphilic drugs (CADs) through inhibition of lysosomal phospholipase activity.
- While biochemical and ultrastructural changes are known, the organismal effects of phospholipidosis are less understood.
Purpose of the Study:
- To review the current knowledge on the functional consequences of drug-induced phospholipidosis.
- To evaluate the impact of cationic amphiphilic drugs on biological systems.
- To highlight the significance of phospholipidosis in pharmaceutical preclinical testing.
Main Methods:
- Literature review of studies on cationic amphiphilic drugs and phospholipidosis.
- Analysis of biochemical and ultrastructural data related to drug-induced phospholipidosis.
- Evaluation of existing research on the physiological effects of phospholipidosis in organisms.
Main Results:
- Cationic amphiphilic drugs (CADs) are known to induce phospholipidosis by inhibiting lysosomal phospholipase.
- The condition involves intracellular accumulation of phospholipids and formation of concentric lamellar bodies.
- Limited data exists on the adverse functional consequences of phospholipidosis at the organismal level.
Conclusions:
- Understanding the functional consequences of CAD-induced phospholipidosis is crucial for drug safety assessment.
- Further research is needed to elucidate the adverse effects of phospholipidosis on biological organisms.
- This review provides an evaluation of the current state of knowledge on this topic.
Related Concept Videos
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
291
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
291
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
333
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
01:27Synthesis of Phosphatidylcholine in the ER Membrane
4.6K
The ER synthesizes lipids for building cell membranes and performing cellular functions such as energy storage and signaling. The lipid synthesis machinery embedded in the ER membrane primarily collects all reactants from the cytosol. Following synthesis, the secretory pathway and the ER contact sites distribute these lipids to other cellular organelles. Additionally, the energy-rich triacylglycerides are transported from the ER via lipid droplets.
The major components of all eukaryotic cell...
The major components of all eukaryotic cell...
4.6K
01:16Drug Biotransformation: Overview
4.2K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.2K
01:28Overview of Fatty Acid Metabolism
37.7K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
37.7K